IMV Inc. (NASDAQ:IMV) reported Q2 EPS of ($0.12), $0.01 better than the analyst estimate of ($0.13). Revenue for the quarter came in at $34 thousand versus the consensus estimate...
Although the stock market indices are quite strong, there are some reasons to be worried about the economic outlook. Thus, investors should use this as an opportunity to cut some...
IMV Inc. (Nasdaq: NASDAQ:IMV), a clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and...
IMV (NASDAQ:IMV) Inc. (“IMV” or the “Company”) (IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid...
IMV Inc. (NASDAQ:IMV) today announced changes to its board of directors as Shermaine Tilley, Ph.D., MBA has resigned from the Board of Directors ("Board") of the Company, effective...